These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24327695)

  • 1. Personalized therapy for acute myeloid leukemia.
    Hourigan CS; Karp JE
    Cancer Discov; 2013 Dec; 3(12):1336-8. PubMed ID: 24327695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.
    Pemovska T; Kontro M; Yadav B; Edgren H; Eldfors S; Szwajda A; Almusa H; Bespalov MM; Ellonen P; Elonen E; Gjertsen BT; Karjalainen R; Kulesskiy E; Lagström S; Lehto A; Lepistö M; Lundán T; Majumder MM; Marti JM; Mattila P; Murumägi A; Mustjoki S; Palva A; Parsons A; Pirttinen T; Rämet ME; Suvela M; Turunen L; Västrik I; Wolf M; Knowles J; Aittokallio T; Heckman CA; Porkka K; Kallioniemi O; Wennerberg K
    Cancer Discov; 2013 Dec; 3(12):1416-29. PubMed ID: 24056683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
    Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S
    Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of acute myeloid leukemia in the next decade - Towards real-time functional testing and personalized medicine.
    Lam SS; He AB; Leung AY
    Blood Rev; 2017 Nov; 31(6):418-425. PubMed ID: 28797519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia.
    Lee SI; Celik S; Logsdon BA; Lundberg SM; Martins TJ; Oehler VG; Estey EH; Miller CP; Chien S; Dai J; Saxena A; Blau CA; Becker PS
    Nat Commun; 2018 Jan; 9(1):42. PubMed ID: 29298978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study.
    Collignon A; Hospital MA; Montersino C; Courtier F; Charbonnier A; Saillard C; D'Incan E; Mohty B; Guille A; Adelaïde J; Carbuccia N; Garnier S; Mozziconacci MJ; Zemmour C; Pakradouni J; Restouin A; Castellano R; Chaffanet M; Birnbaum D; Collette Y; Vey N
    Blood Cancer J; 2020 Jun; 10(6):64. PubMed ID: 32488055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalizing therapy for older adults with acute myeloid leukemia: Role of geriatric assessment and genetic profiling.
    Bhatt VR
    Cancer Treat Rev; 2019 May; 75():52-61. PubMed ID: 31003190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision medicine for acute myeloid leukemia.
    Lai C; Karp JE; Hourigan CS
    Expert Rev Hematol; 2016 Jan; 9(1):1-3. PubMed ID: 26514194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy.
    Bret C; Viziteu E; Kassambara A; Moreaux J
    Expert Rev Hematol; 2016; 9(4):351-60. PubMed ID: 26761438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?
    Megías-Vericat JE; Martínez-Cuadrón D; Solana-Altabella A; Montesinos P
    Expert Rev Hematol; 2020 Oct; 13(10):1057-1065. PubMed ID: 32869672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.
    Scholl S; Spies-Weisshart B; Klink A; Muegge LO; Fricke HJ; Hochhaus A
    Ann Hematol; 2011 Apr; 90(4):473-5. PubMed ID: 20652568
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute Myeloid Leukemia: Changing Treatment Paradigms and Novel Agents in Development.
    Konig H; Zeidner JF
    Curr Cancer Drug Targets; 2020; 20(7):471-472. PubMed ID: 32703130
    [No Abstract]   [Full Text] [Related]  

  • 13. Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.
    Swords RT; Azzam D; Al-Ali H; Lohse I; Volmar CH; Watts JM; Perez A; Rodriguez A; Vargas F; Elias R; Vega F; Zelent A; Brothers SP; Abbasi T; Trent J; Rangwala S; Deutsch Y; Conneally E; Drusbosky L; Cogle CR; Wahlestedt C
    Leuk Res; 2018 Jan; 64():34-41. PubMed ID: 29175379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drugs for acute myeloid leukemia inspired by genomics and when to use them.
    Pollyea DA
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):45-50. PubMed ID: 30504290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision therapy for acute myeloid leukemia.
    Yang X; Wang J
    J Hematol Oncol; 2018 Jan; 11(1):3. PubMed ID: 29301553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro all-trans retinoic acid sensitivity of acute myeloid leukemia blasts with NUP98/RARG fusion gene.
    Such E; Cordón L; Sempere A; Villamón E; Ibañez M; Luna I; Gómez-Seguí I; López-Pavía M; Alonso C; Lo-Coco F; Cervera J; Sanz MA
    Ann Hematol; 2014 Nov; 93(11):1931-3. PubMed ID: 24728721
    [No Abstract]   [Full Text] [Related]  

  • 17. Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia.
    Benard BA; Leak LB; Azizi A; Thomas D; Gentles AJ; Majeti R
    Nat Commun; 2021 Dec; 12(1):7244. PubMed ID: 34903734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.
    Grunwald MR; Levis MJ
    Int J Hematol; 2013 Jun; 97(6):683-94. PubMed ID: 23613268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones.
    Ianevski A; Nader K; Driva K; Senkowski W; Bulanova D; Moyano-Galceran L; Ruokoranta T; Kuusanmäki H; Ikonen N; Sergeev P; Vähä-Koskela M; Giri AK; Vähärautio A; Kontro M; Porkka K; Pitkänen E; Heckman CA; Wennerberg K; Aittokallio T
    Nat Commun; 2024 Oct; 15(1):8579. PubMed ID: 39362905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions.
    Bhatla T; Jones CL; Meyer JA; Vitanza NA; Raetz EA; Carroll WL
    J Pediatr Hematol Oncol; 2014 Aug; 36(6):413-8. PubMed ID: 24942023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.